Acute graft-versus-host disease (GVHD) is a common immune complication that can occur
after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major …

An essential component of allogeneic and autologous hematopoietic cell transplantation
(HCT) is the conditioning regimen administered before the hematopoietic cell infusion. Early …

Prior studies suggest increased cytomegalovirus (CMV) infection after haploidentical donor
transplantation with posttransplant cyclophosphamide (HaploCy). The role of allograft …

Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk
haematological malignant disorders and other life-threatening haematological and genetic …

To complement the existing treatment guidelines for all tumour types, ESMO organizes
consensus conferences to focus on specific issues in each type of tumour. In this setting, a …

Although the majority of patients with acute myeloid leukemia (AML) treated with intensive
chemotherapy achieve a complete remission (CR), many are destined to relapse if treated …

The success of reduced intensity conditioning (RIC) transplantation is largely dependent on
alloimmune effects. It is critical to determine whether immune modulation with anti–T-cell …

Graft-versus-host disease (GvHD) was first described in 1959, since then major efforts have
been made in order to understand its physiopathology and animal models have played a …

Acute graft-versus-host disease (GVHD) occurs after allogeneic hematopoietic stem cell
transplant and is a reaction of donor immune cells against host tissues. Activated donor T …

In this multicenter retrospective study, the outcomes of 836 patients with myelodysplastic
syndrome (MDS) who underwent transplantation with a human leukocyte antigen (HLA) …